<コード>Stock name closing price on the 11th ⇒ compared to the previous day

PeptiDream ＜4587＞ 2664.5 -145.0

In particular, no materials were observed, and it was a supply-demand factor.

Sumitomo Forestry ＜1911＞ 5710 -191

I was wary of the financial results of the US Toll Brothers.

LIFUL＜2120＞ 193 -5

The sense that the upper price has been reached has also spread, and there is an advantage in closeout sales.

Lax ＜3923＞ 1924 -74

Growth stocks are weak due to rising long-term US interest rates.

Sun Wells ＜9229＞ 813 -34

The soft ground for small to medium growth is also a headwind.

Shinko Kogyo ＜6458＞ 1200 -37

Lower price anxiety intensified after breaking through the November low.

Bay Current ＜6532＞ 5377 -203

Closeout sales are an advantage in small to medium growth.

Euglena ＜2931＞ 405 -10

The rise on the 10th was also blocked by the 25-day line level.

DMG Mori Seiki ＜6141＞ 2515 -62.5

SMBC Nikko Securities downgraded investment decisions.

Disco ＜6146＞ 40410 -1530

The depreciation of overseas semiconductor stocks also spread to domestic-related stocks.

Micronics Japan ＜6871＞ 3600 -10

The trend of depreciation in semiconductor-related stocks has spread.

Temona ＜3985＞ 226 +37

An unauthorized order detection service is provided to the Subscription Promotion Association platform.

Fourside ＜2330＞ 167 +26

A movement to increase the price range of short-term funds aimed at a rebound.

Aisan Techno ＜4667＞ 1657 +45

The speed adjustment round once again led to the upper price advantage.

CLHD＜4286＞ 741-109

Disgusted with drastic downward revisions and dividend cuts.

Disruptors ＜6538＞ 169 -20

On the 10th, they went backstage and grew rapidly, and short-term funds had an advantage over profit.

Tobira Systems ＜4441＞ 779 -66

The forecast for a slowdown in earnings growth for the current fiscal year was viewed as negative.

Trial ＜141A＞ 2963 +36

The growth rate expanded from a 5.0% increase in existing store sales in November and a 0.8% increase in October.

The upper price is heavy.

Helios ＜4593＞ 180 -9

It was selected as an open call project by the Japan Agency for Medical Research and Development and will be purchased on the 10th.

Sales advantage on the 11th.

VALUENEX＜4422＞ 664 -53

Operating profit and loss for the first quarter were in deficit of 0.068 billion yen.

J Frontier ＜2934＞ 1344 -156

Submit the securities report for the fiscal year ending 24/5, which had been delayed,

Expected to maintain the listing.

R Planner ＜2983＞ 1390 -34

Earnings and dividend forecasts for the fiscal year ending 25/1 were revised upward, making it popular on the 10th.

Sales advantage on the 11th.

GENDA＜9166＞ 2514 -39

Third-quarter cumulative operating profit increased 30.1%.

AviC＜9554＞ 1268 +38

Presented the way of thinking and achievements in AI product development.

Tim's 4891 218 +4

Administration of TMS-008 to all subjects was completed in the Phase 1 clinical trial.

It started rising, but buying didn't continue.

Asukanet [2438] 450 -11

The rate of progress for the first half of the year compared to the full-year forecast operating profit remained at 2.8%

It will be sold in 10 days. Sales advantage was also on the 11th.

Perseus (4882) 725 -17

PPMX-T003 polycythemia vera phase 1 trial was reported at the American Society of Hematology.

Even though it starts rising, the upper price is heavy.